Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Comparison with Other Therapies Phase 1 trials demonstrated that Retatrutides safety profile was comparable to other GLP-1 receptor agonists, with no unexpected safety signals identified
Many patients find they need reminders since reduced eating often means reduced drinking
The result: patients eat significantly less, lose weight, and experience improvements in blood sugar control
Omland et al, 2000)
Glucose (0.2g/mL) was injected intraperitoneally according to body weight (100L/10g)
Semaglutide has been shown to result in the highest total body weight loss percentage of around 14.9%, within FDA-approved anti-obesity medications
US$ 20.96
US$ 25.40
US$ 29.74
US$ 21.56
US$ 22.61
US$ 24.44
US$ 26.46
US$ 21.92
